Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis

Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; p. 765
Main Authors Pan, Bo, Sun, Pan, Pei, Renjun, Lin, Fangzhao, Cao, Haijun
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.10.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies. A systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated. In total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77-0.95, p = 0.005), the hospital stay (MD - 4.46, 95% CI: - 6.35 to - 2.57, p = 0.00001), and the APACHE II scores (MD - 1.65, 95% CI: - 2.89 to - 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 - 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81-1.02, p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81-1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57-0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79-0.99, p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28-0.84, p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27-1.14, p = 0.11). There is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries.
AbstractList BACKGROUNDSepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies.METHODSA systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated.RESULTSIn total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77-0.95, p = 0.005), the hospital stay (MD - 4.46, 95% CI: - 6.35 to - 2.57, p = 0.00001), and the APACHE II scores (MD - 1.65, 95% CI: - 2.89 to - 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 - 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81-1.02, p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81-1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57-0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79-0.99, p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28-0.84, p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27-1.14, p = 0.11).CONCLUSIONSThere is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries.
Abstract Background Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies. Methods A systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated. Results In total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77–0.95, p = 0.005), the hospital stay (MD − 4.46, 95% CI: − 6.35 to − 2.57, p = 0.00001), and the APACHE II scores (MD − 1.65, 95% CI: − 2.89 to − 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 − 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81–1.02, p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81–1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57–0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79–0.99, p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28–0.84, p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27–1.14, p = 0.11). Conclusions There is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries.
Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies. A systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated. In total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77-0.95, p = 0.005), the hospital stay (MD - 4.46, 95% CI: - 6.35 to - 2.57, p = 0.00001), and the APACHE II scores (MD - 1.65, 95% CI: - 2.89 to - 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 - 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81-1.02, p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81-1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57-0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79-0.99, p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28-0.84, p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27-1.14, p = 0.11). There is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries.
Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies. A systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated. In total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77-0.95, p = 0.005), the hospital stay (MD - 4.46, 95% CI: - 6.35 to - 2.57, p = 0.00001), and the APACHE II scores (MD - 1.65, 95% CI: - 2.89 to - 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 - 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81-1.02, p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81-1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57-0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79-0.99, p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28-0.84, p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27-1.14, p = 0.11). There is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries.
BackgroundSepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies.MethodsA systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated.ResultsIn total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77–0.95, p = 0.005), the hospital stay (MD − 4.46, 95% CI: − 6.35 to − 2.57, p = 0.00001), and the APACHE II scores (MD − 1.65, 95% CI: − 2.89 to − 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 − 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81–1.02,p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81–1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57–0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79–0.99,p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28–0.84,p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27–1.14,p = 0.11).ConclusionsThere is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries.
Background Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients. Results of trials on IVIG as adjunctive therapy for sepsis have been conflicting due to the variability in population characteristics, country geography and drug dosage form in different studies. Methods A systematic article search was performed for eligible studies published up to January, 31, 2023, through the PubMed, Embase, Cochrane Library and Chinese National Knowledge Infrastructure database. The included articles were screened by using rigorous inclusion and exclusion criteria. Subgroup analyses were conducted according to different IVIG types, ages and economic regions. All analyses were conducted using Review Manager 5.4. Quality of studies and risk of bias were evaluated. Results In total, 31 randomized controlled trials were included with a sample size of 6,276 participants. IVIG could reduce the mortality (RR 0.86, 95% CI: 0.77-0.95, p = 0.005), the hospital stay (MD - 4.46, 95% CI: - 6.35 to - 2.57, p = 0.00001), and the APACHE II scores (MD - 1.65, 95% CI: - 2.89 to - 0.63, p = 0.001). Additionally, the results showed that IgM-enriched IVIG was effective in treating sepsis (RR 0.55, 95% CI: 0.40 - 0.76; p = 0.0003), while standard IVIG failed to be effective (RR 0.91, 95% CI: 0.81-1.02, p = 0.10). And the effect of IVIG in reducing neonatal mortality was inconclusive (RR 0.93, 95% CI: 0.81-1.05, p = 0.24), but it played a large role in reducing sepsis mortality in adults (RR 0.70, 95% CI: 0.57-0.86, p = 0.0006). Besides, from the subgroup of different economic regions, it indicated that IVIG was effective for sepsis in high-income (RR 0.89, 95% CI: 0.79-0.99, p = 0.03) and middle-income countries (RR 0.49, 95% CI: 0.28-0.84, p = 0.01), while no benefit was demonstrated in low-income countries (RR 0.56, 95% CI: 0.27-1.14, p = 0.11). Conclusions There is sufficient evidence to support that IVIG reduces sepsis mortality. IgM-enriched IVIG is effective in both adult and neonatal sepsis, while standard IVIG is only effective in adult sepsis. IVIG for sepsis has shown efficacy in high- and middle-income countries, but is still debatable in low-income countries. More RCTs are needed in the future to confirm the true clinical potential of IVIG for sepsis in low-income countries. Keywords: IVIG, Sepsis, Age-difference, Economic regions, Meta-analysis
ArticleNumber 765
Audience Academic
Author Lin, Fangzhao
Cao, Haijun
Pan, Bo
Sun, Pan
Pei, Renjun
Author_xml – sequence: 1
  givenname: Bo
  surname: Pan
  fullname: Pan, Bo
  organization: Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, 610052, China
– sequence: 2
  givenname: Pan
  surname: Sun
  fullname: Sun, Pan
  organization: Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, 610052, China
– sequence: 3
  givenname: Renjun
  surname: Pei
  fullname: Pei, Renjun
  organization: Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, 610052, China
– sequence: 4
  givenname: Fangzhao
  surname: Lin
  fullname: Lin, Fangzhao
  email: lfangzhao@126.com
  organization: Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, 610052, China. lfangzhao@126.com
– sequence: 5
  givenname: Haijun
  surname: Cao
  fullname: Cao, Haijun
  email: chjr007@163.com
  organization: Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, 610052, China. chjr007@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37898763$$D View this record in MEDLINE/PubMed
BookMark eNptkk9v1DAQxSNURP_AF-CALHHpJcXjOInDBVVVaVeqxAUQN2tqj3e9SuLFzrbab4-325YuQj7YGr_3s2f0jouDMYxUFO-BnwGo5lMC0TVtyUVVcll3olSviiOQbVfWqm0OXpwPi-OUlpwLWcvuTXFYtarL5eqo-HXpnDdoNiw4Nvs5u2LTgiKuNsyFyFY4eRqnxO79tGCJVsmnzwxZ2qSJhnxpWKQ7T_cMR8sGmrDEEftNlr0tXjvsE7173E-KH18vv19clzffrmYX5zelqRs5lSg71xrl6BZAONlap-oKLaJwZIlUCx04XtuGoxHADXESxtTcWnAkHFYnxWzHtQGXehX9gHGjA3r9UAhxrjHmj_akeQNNBZWDPBIpMMOl5I10qDprhIDM-rJjrda3A1mTW4_Y70H3b0a_0PNwpyGjRcVlJpw-EmL4vaY06cEnQ32PI4V10kKpqlbQSp6lH_-RLsM65ultVR0HACm7v6o55g786EJ-2Gyh-rxteaNAia3q7D-qvCwN3uTUOJ_rewaxM5gYUorknpsErrfh0rtw6Rwu_RAurbLpw8vxPFue0lT9Afm2yyo
CitedBy_id crossref_primary_10_15360_1813_9779_2024_3_2388
crossref_primary_10_3389_fimmu_2024_1391395
Cites_doi 10.3329/jbcps.v24i3.158
10.1111/j.1423-0410.1981.tb00717.x
10.1002/14651858.CD013837.pub2
10.1186/cc1523
10.1016/S0140-6736(17)31002-4
10.1007/s12016-015-8499-2
10.1007/s00540-012-1553-9
10.1002/14651858.CD001090.pub2
10.1097/01.CCM.0000215452.84291.C6
10.1086/376630
10.3233/NPM-221025
10.1097/01.shk.0000157302.69125.f8
10.1001/archsurg.1991.01410260126018
10.1016/S0140-6736(19)32989-7
10.1007/s00134-022-06956-y
10.1007/BF01711930
10.1097/CCM.0000000000001142
10.1016/S1473-3099(15)70112-X
10.3310/hta16070
10.1038/s41390-021-01696-z
10.3389/fimmu.2023.1166821
10.1371/journal.pmed.1000097
10.1164/rccm.201504-0781OC
10.1007/s00134-017-4683-6
10.1055/s-0033-1363771
10.1097/PCC.0000000000000254
10.1371/journal.pone.0244109
10.1007/BF00918802
10.4103/ijp.ijp_881_20
10.1097/00003246-199302001-00007
10.3389/fimmu.2022.1016877
10.1097/00003246-198801000-00005
10.1016/s0022-3476(05)83389-x
10.33192/Smj.2021.12
10.1186/s13054-014-0649-z
10.1186/cc1837
10.1089/sur.2017.316
10.1001/jama.2016.0289
10.1186/s40779-022-00422-y
10.1007/s00253-011-3185-7
10.1056/NEJMoa1100441
10.1177/0009922817702940
10.1016/s0022-3476(05)81802-5
10.1097/00003246-200712000-00026
10.1001/archpedi.1988.02150120047038
10.1136/ebmed-2016-110401
10.3233/NPM-190259
10.1128/AAC.36.10.2139
10.7189/jogh.02.010404
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12967-023-04592-8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Databases
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
Immunology Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 765
ExternalDocumentID oai_doaj_org_article_0616313f158742ae8744064fa89dc221
A770681829
10_1186_s12967_023_04592_8
37898763
Genre Meta-Analysis
Review
Research Support, Non-U.S. Gov't
Systematic Review
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: CIFMS; 2021-I2M-1-060
– fundername: ;
  grantid: 2019YFS0105
– fundername: ;
  grantid: CSBT-WG-2021-02
GroupedDBID ---
-A0
0R~
29L
2WC
3V.
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACRMQ
ADBBV
ADINQ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
AAYXX
CITATION
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c564t-a49f7c8feb112f47df853adaa2fedee87191f05d60ac210ce0e2cc50dd1fe2fa3
IEDL.DBID RPM
ISSN 1479-5876
IngestDate Tue Oct 22 15:10:58 EDT 2024
Tue Sep 17 21:29:31 EDT 2024
Sat Oct 26 06:08:17 EDT 2024
Thu Oct 10 18:07:33 EDT 2024
Tue Nov 19 21:45:10 EST 2024
Wed Nov 13 00:14:23 EST 2024
Thu Nov 21 22:41:33 EST 2024
Sat Nov 02 12:29:52 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords IVIG
Sepsis
Economic regions
Age-difference
Meta-analysis
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-a49f7c8feb112f47df853adaa2fedee87191f05d60ac210ce0e2cc50dd1fe2fa3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ObjectType-Undefined-4
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612304/
PMID 37898763
PQID 2890111449
PQPubID 43076
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_0616313f158742ae8744064fa89dc221
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10612304
proquest_miscellaneous_2883581740
proquest_journals_2890111449
gale_infotracmisc_A770681829
gale_infotracacademiconefile_A770681829
crossref_primary_10_1186_s12967_023_04592_8
pubmed_primary_37898763
PublicationCentury 2000
PublicationDate 2023-10-28
PublicationDateYYYYMMDD 2023-10-28
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References LE Weisman (4592_CR49) 1992; 121
D Moher (4592_CR21) 2009; 6
S Karatzas (4592_CR39) 2002; 6
IH Celik (4592_CR19) 2022; 91
KF Nassir (4592_CR18) 2021; 53
A Bancalari (4592_CR25) 2020; 13
JY Chen (4592_CR29) 1996; 95
ER Burns (4592_CR28) 1991; 11
I Toth (4592_CR47) 2013; 27
T Masaoka (4592_CR42) 2000; 48
MH Murad (4592_CR17) 2016; 21
M Yakut (4592_CR52) 1998; 40
RD Christensen (4592_CR30) 1991; 118
M Hentrich (4592_CR37) 2006; 34
S Von Gunten (4592_CR10) 2023; 14
I Jawad (4592_CR3) 2012; 2
MM Alejandria (4592_CR12) 2013
A Rhodes (4592_CR16) 2017; 43
SA Sterling (4592_CR7) 2015; 43
J Mancilla-Ramirez (4592_CR41) 1992; 49
A Akdag (4592_CR24) 2014; 31
SK Korang (4592_CR6) 2021; 5
HM Just (4592_CR38) 1986; 64
KA Schuller (4592_CR55) 2017; 56
4592_CR22
J Darenberg (4592_CR31) 2003; 37
P Brocklehurst (4592_CR27) 2011; 365
S Ahmed (4592_CR23) 2007
D Liu (4592_CR8) 2022; 9
L Lindquist (4592_CR40) 1981; 40
M Singer (4592_CR4) 2016; 315
P Póvoa (4592_CR1) 2023; 49
J Cohen (4592_CR9) 2015; 15
HM Nabwera (4592_CR57) 2021; 16
L Dominioni (4592_CR33) 1991; 126
R Grundmann (4592_CR35) 1988; 272
A Rodríguez (4592_CR43) 2005; 23
MO Soares (4592_CR15) 2012; 16
G Behre (4592_CR26) 1995; 13
C Wesoly (4592_CR51) 1990; 23
PH Wong (4592_CR58) 2016; 51
K Werdan (4592_CR50) 2007; 35
MP Fink (4592_CR13) 1993; 21
C Fleischmann (4592_CR2) 2016; 193
K Brandenburg (4592_CR11) 2011; 90
S Tugrul (4592_CR48) 2002; 6
BM Emr (4592_CR56) 2018; 19
T Abiramalatha (4592_CR5) 2022; 15
C Boonsopa (4592_CR59) 2021; 72
KN Haque (4592_CR36) 1988; 142
D Sidiropoulos (4592_CR46) 1981; 111
MO Soares (4592_CR14) 2014; 18
A Ruth (4592_CR54) 2014; 15
KE Rudd (4592_CR60) 2020; 395
C De Simone (4592_CR32) 1988; 16
A Akdag (4592_CR44) 1997; 11
AL Shane (4592_CR20) 2017; 390
A Shenoi (4592_CR45) 1999; 36
G Erdem (4592_CR34) 1993; 35
CR Beudeker (4592_CR53) 2022; 13
References_xml – ident: 4592_CR22
– year: 2007
  ident: 4592_CR23
  publication-title: J Bangladesh Coll Phys Surg
  doi: 10.3329/jbcps.v24i3.158
  contributor:
    fullname: S Ahmed
– volume: 40
  start-page: 329
  issue: 5
  year: 1981
  ident: 4592_CR40
  publication-title: Vox Sang
  doi: 10.1111/j.1423-0410.1981.tb00717.x
  contributor:
    fullname: L Lindquist
– volume: 5
  start-page: CD013837
  issue: 5
  year: 2021
  ident: 4592_CR6
  publication-title: Cochrane Database Syst Rev
  doi: 10.1002/14651858.CD013837.pub2
  contributor:
    fullname: SK Korang
– volume: 6
  start-page: 357
  issue: 4
  year: 2002
  ident: 4592_CR48
  publication-title: Crit Care
  doi: 10.1186/cc1523
  contributor:
    fullname: S Tugrul
– volume: 49
  start-page: 4
  issue: 1
  year: 1992
  ident: 4592_CR41
  publication-title: Boletin medico del Hospital Infantil de Mexico
  contributor:
    fullname: J Mancilla-Ramirez
– volume: 390
  start-page: 1770
  issue: 10104
  year: 2017
  ident: 4592_CR20
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)31002-4
  contributor:
    fullname: AL Shane
– volume: 51
  start-page: 303
  issue: 3
  year: 2016
  ident: 4592_CR58
  publication-title: Clin Rev Allergy Immunol
  doi: 10.1007/s12016-015-8499-2
  contributor:
    fullname: PH Wong
– volume: 111
  start-page: 1649
  issue: 44
  year: 1981
  ident: 4592_CR46
  publication-title: Schweizerische medizinische Wochenschrift
  contributor:
    fullname: D Sidiropoulos
– volume: 27
  start-page: 618
  issue: 4
  year: 2013
  ident: 4592_CR47
  publication-title: J Anesth
  doi: 10.1007/s00540-012-1553-9
  contributor:
    fullname: I Toth
– year: 2013
  ident: 4592_CR12
  publication-title: Cochrane Database Syst Rev
  doi: 10.1002/14651858.CD001090.pub2
  contributor:
    fullname: MM Alejandria
– volume: 34
  start-page: 1319
  issue: 5
  year: 2006
  ident: 4592_CR37
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000215452.84291.C6
  contributor:
    fullname: M Hentrich
– volume: 35
  start-page: 277
  issue: 4
  year: 1993
  ident: 4592_CR34
  publication-title: Turk J Pediatrics
  contributor:
    fullname: G Erdem
– volume: 23
  start-page: 213
  issue: 4
  year: 1990
  ident: 4592_CR51
  publication-title: Zeitschrift fur experimentelle Chirurgie, Transplantation, und kunstliche Organe
  contributor:
    fullname: C Wesoly
– volume: 37
  start-page: 333
  issue: 3
  year: 2003
  ident: 4592_CR31
  publication-title: Clin Infect Dis
  doi: 10.1086/376630
  contributor:
    fullname: J Darenberg
– volume: 15
  start-page: 699
  issue: 4
  year: 2022
  ident: 4592_CR5
  publication-title: J Neonatal Perinatal Med
  doi: 10.3233/NPM-221025
  contributor:
    fullname: T Abiramalatha
– volume: 23
  start-page: 298
  issue: 4
  year: 2005
  ident: 4592_CR43
  publication-title: Shock (Augusta, Ga)
  doi: 10.1097/01.shk.0000157302.69125.f8
  contributor:
    fullname: A Rodríguez
– volume: 126
  start-page: 236
  issue: 2
  year: 1991
  ident: 4592_CR33
  publication-title: Arch Surg
  doi: 10.1001/archsurg.1991.01410260126018
  contributor:
    fullname: L Dominioni
– volume: 395
  start-page: 200
  issue: 10219
  year: 2020
  ident: 4592_CR60
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32989-7
  contributor:
    fullname: KE Rudd
– volume: 49
  start-page: 142
  issue: 2
  year: 2023
  ident: 4592_CR1
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-022-06956-y
  contributor:
    fullname: P Póvoa
– volume: 64
  start-page: 245
  issue: 6
  year: 1986
  ident: 4592_CR38
  publication-title: Klin Wochenschr
  doi: 10.1007/BF01711930
  contributor:
    fullname: HM Just
– volume: 43
  start-page: 1907
  issue: 9
  year: 2015
  ident: 4592_CR7
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000001142
  contributor:
    fullname: SA Sterling
– volume: 15
  start-page: 581
  issue: 5
  year: 2015
  ident: 4592_CR9
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(15)70112-X
  contributor:
    fullname: J Cohen
– volume: 16
  start-page: 1
  issue: 7
  year: 2012
  ident: 4592_CR15
  publication-title: Health Technol Assess
  doi: 10.3310/hta16070
  contributor:
    fullname: MO Soares
– volume: 91
  start-page: 337
  issue: 2
  year: 2022
  ident: 4592_CR19
  publication-title: Pediatr Res
  doi: 10.1038/s41390-021-01696-z
  contributor:
    fullname: IH Celik
– volume: 14
  start-page: 1166821
  year: 2023
  ident: 4592_CR10
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1166821
  contributor:
    fullname: S Von Gunten
– volume: 6
  issue: 7
  year: 2009
  ident: 4592_CR21
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000097
  contributor:
    fullname: D Moher
– volume: 193
  start-page: 259
  issue: 3
  year: 2016
  ident: 4592_CR2
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201504-0781OC
  contributor:
    fullname: C Fleischmann
– volume: 43
  start-page: 304
  issue: 3
  year: 2017
  ident: 4592_CR16
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-017-4683-6
  contributor:
    fullname: A Rhodes
– volume: 11
  start-page: 1
  year: 1997
  ident: 4592_CR44
  publication-title: Am J Perinatol
  doi: 10.1055/s-0033-1363771
  contributor:
    fullname: A Akdag
– volume: 15
  start-page: 828
  issue: 9
  year: 2014
  ident: 4592_CR54
  publication-title: Pediatr Crit Care Med
  doi: 10.1097/PCC.0000000000000254
  contributor:
    fullname: A Ruth
– volume: 16
  issue: 1
  year: 2021
  ident: 4592_CR57
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0244109
  contributor:
    fullname: HM Nabwera
– volume: 11
  start-page: 363
  issue: 6
  year: 1991
  ident: 4592_CR28
  publication-title: J Clin Immunol
  doi: 10.1007/BF00918802
  contributor:
    fullname: ER Burns
– volume: 272
  start-page: 339
  year: 1988
  ident: 4592_CR35
  publication-title: Prog Clin Biol Res
  contributor:
    fullname: R Grundmann
– volume: 53
  start-page: 364
  issue: 5
  year: 2021
  ident: 4592_CR18
  publication-title: Indian J Pharmacol
  doi: 10.4103/ijp.ijp_881_20
  contributor:
    fullname: KF Nassir
– volume: 21
  start-page: S32
  issue: 2 Suppl
  year: 1993
  ident: 4592_CR13
  publication-title: Crit Care Med
  doi: 10.1097/00003246-199302001-00007
  contributor:
    fullname: MP Fink
– volume: 13
  start-page: 1016877
  year: 2022
  ident: 4592_CR53
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.1016877
  contributor:
    fullname: CR Beudeker
– volume: 16
  start-page: 23
  issue: 1
  year: 1988
  ident: 4592_CR32
  publication-title: Crit Care Med
  doi: 10.1097/00003246-198801000-00005
  contributor:
    fullname: C De Simone
– volume: 118
  start-page: 606
  issue: 4 Pt 1
  year: 1991
  ident: 4592_CR30
  publication-title: J Pediatr
  doi: 10.1016/s0022-3476(05)83389-x
  contributor:
    fullname: RD Christensen
– volume: 72
  start-page: 84
  year: 2021
  ident: 4592_CR59
  publication-title: Siriraj Med J
  doi: 10.33192/Smj.2021.12
  contributor:
    fullname: C Boonsopa
– volume: 18
  start-page: 649
  issue: 6
  year: 2014
  ident: 4592_CR14
  publication-title: Crit Care
  doi: 10.1186/s13054-014-0649-z
  contributor:
    fullname: MO Soares
– volume: 6
  start-page: 543
  issue: 6
  year: 2002
  ident: 4592_CR39
  publication-title: Crit Care
  doi: 10.1186/cc1837
  contributor:
    fullname: S Karatzas
– volume: 19
  start-page: 176
  issue: 2
  year: 2018
  ident: 4592_CR56
  publication-title: Surg Infect (Larchmt)
  doi: 10.1089/sur.2017.316
  contributor:
    fullname: BM Emr
– volume: 95
  start-page: 839
  issue: 11
  year: 1996
  ident: 4592_CR29
  publication-title: J Formosan Med Assoc / Taiwan yi zhi
  contributor:
    fullname: JY Chen
– volume: 315
  start-page: 801
  issue: 8
  year: 2016
  ident: 4592_CR4
  publication-title: JAMA
  doi: 10.1001/jama.2016.0289
  contributor:
    fullname: M Singer
– volume: 9
  start-page: 56
  issue: 1
  year: 2022
  ident: 4592_CR8
  publication-title: Mil Med Res
  doi: 10.1186/s40779-022-00422-y
  contributor:
    fullname: D Liu
– volume: 90
  start-page: 799
  issue: 3
  year: 2011
  ident: 4592_CR11
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-011-3185-7
  contributor:
    fullname: K Brandenburg
– volume: 365
  start-page: 1201
  issue: 13
  year: 2011
  ident: 4592_CR27
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1100441
  contributor:
    fullname: P Brocklehurst
– volume: 56
  start-page: 1001
  issue: 11
  year: 2017
  ident: 4592_CR55
  publication-title: Clin Pediatr (Phila)
  doi: 10.1177/0009922817702940
  contributor:
    fullname: KA Schuller
– volume: 48
  start-page: 199
  issue: 3
  year: 2000
  ident: 4592_CR42
  publication-title: Jpn J Chemother
  contributor:
    fullname: T Masaoka
– volume: 121
  start-page: 434
  issue: 3
  year: 1992
  ident: 4592_CR49
  publication-title: J Pediatr
  doi: 10.1016/s0022-3476(05)81802-5
  contributor:
    fullname: LE Weisman
– volume: 35
  start-page: 2693
  issue: 12
  year: 2007
  ident: 4592_CR50
  publication-title: Crit Care Med
  doi: 10.1097/00003246-200712000-00026
  contributor:
    fullname: K Werdan
– volume: 142
  start-page: 1293
  issue: 12
  year: 1988
  ident: 4592_CR36
  publication-title: Am J Dis Child (1960)
  doi: 10.1001/archpedi.1988.02150120047038
  contributor:
    fullname: KN Haque
– volume: 21
  start-page: 125
  issue: 4
  year: 2016
  ident: 4592_CR17
  publication-title: Evid Based Med
  doi: 10.1136/ebmed-2016-110401
  contributor:
    fullname: MH Murad
– volume: 13
  start-page: 381
  issue: 3
  year: 2020
  ident: 4592_CR25
  publication-title: J Neonatal-perinatal Med
  doi: 10.3233/NPM-190259
  contributor:
    fullname: A Bancalari
– volume: 40
  start-page: 76
  issue: 1
  year: 1998
  ident: 4592_CR52
  publication-title: Bull Gulhane Military Med Acad
  contributor:
    fullname: M Yakut
– volume: 13
  start-page: 129
  issue: 2
  year: 1995
  ident: 4592_CR26
  publication-title: Antiinfective Drugs Chemother
  doi: 10.1128/AAC.36.10.2139
  contributor:
    fullname: G Behre
– volume: 36
  start-page: 1113
  issue: 11
  year: 1999
  ident: 4592_CR45
  publication-title: Indian Pediatr
  contributor:
    fullname: A Shenoi
– volume: 31
  start-page: 905
  issue: 10
  year: 2014
  ident: 4592_CR24
  publication-title: Am J Perinatol
  doi: 10.1055/s-0033-1363771
  contributor:
    fullname: A Akdag
– volume: 2
  issue: 1
  year: 2012
  ident: 4592_CR3
  publication-title: J Glob Health
  doi: 10.7189/jogh.02.010404
  contributor:
    fullname: I Jawad
SSID ssj0024549
Score 2.4393342
SecondaryResourceType review_article
Snippet Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes....
Background Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve...
BackgroundSepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve...
BACKGROUNDSepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve...
Abstract Background Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 765
SubjectTerms Age-difference
Antibiotics
Antibodies
Care and treatment
Clinical trials
Drug therapy
Economic regions
Hospitals
Humans
Immunoglobulin M
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Infants
Infants (Newborn)
Intravenous administration
IVIG
Length of Stay
Meta-analysis
Morbidity
Mortality
Neonates
Patient outcomes
Patients
Performance evaluation
Review
Sepsis
Sepsis - drug therapy
Systematic review
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhAXRHmGlspISBxQVMdxbIdbqVpapHKiaG-W44fogWxFtof-e2biZNmIAxcuOcSO5Hxjzzfjx2eAd5IHX1dRl1K2-FDClRiFxLKtlWqNCcl7mhq4-qouruWXVbPaueqL9oRleeAM3DHyjaqrOlWNwSzORZJrRxpNzrTBC5ETHy7mZGpW2cO0Zz4iY9TxgKyGDgH5qcQQpkUfsKChUa3_b5-8Q0rLDZM7DHT-BB5PoSM7yU3ehwexfwoPr6bF8WewOiM5COfv2Tqxy--Xn1k-XHXPMDBlk4DqwGjmlQ3xdrgZPjLH_kg5s3yMhbk-sJ9x40o3CZY8h-vzs2-nF-V0cULpGyU3pZNt0t4k9MOVSFKHhKTsgnMixRARQkzSEm-C4s4jeD7yKLxveAhViiK5-gXs9es-vgLWVLpLmETqBuPEjmtH-yWUjE1XO9WmroAPM472Nutj2DGvMMpm1C2ibkfUrSngE0G9rUna1uMLtLidLG7_ZfEC3pOhLI1AtAbimg8SYINJy8qeaM0VxiGiLeBwURNHjl8Wz6a208gdLC28ov_HrlvA220xfUm70fq4vqM6hmTjtOQFvMw9Y_tLtTYtqfwVYBZ9ZvHPy5L-5seo612NWjhcvv4fKB3AI0H9HWlWmEPY2_y6i28wftp0R-NQ-Q3fyRRZ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Databases
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiDcpBRkJiQOKmjiOH1xQi7a0SK0QomhvluNH6YFk22wP_ffMJN7dRkhccoidyB57Zr4Z258Jec8L76oyyJxzDQ_BbA4oJOS6EkIr5aNzmBo4PRPH5_zbol6khFuftlWubeJgqH3nMEe-jwtioJfwy8_LqxxvjcLV1XSFxn2yw8pKqRnZOZyfff-xZduD8Gd9VEaJ_R68GxgG8FM5QBkNtmDijgbW_n9t8x3nNN04eccTHT0mjxKEpAfjmD8h90L7lDw4TYvkz8hijrQQ1t3SLtKTXydf6XjI6pYCQKWJSLWnmIGlfVj2l_0naumW0pmOx1mobT39E1Y2t4m45Dk5P5r__HKcpwsUclcLvsot11E6FcEelyxy6SM4Z-utZTH4ECBW0mUsai8K6yD0c6EIzLm68L6MgUVbvSCztmvDK0LrUjYRgklZA15sCmlx34TgoW4qK3RsMvJxLUezHHkyzBBfKGFGqRuQuhmkblRGDlHUm5rIcT286K4vTFIZA0hDVGUVy1pB_G4DEvUDgIpWae8YKzPyAQfKoCbCaIBcxwMF0GDktDIHUhYC8AjTGdmb1AQNctPi9VCbpMG92c63jLzbFOOXuCutDd0N1lFIHyd5kZGX48zYdKmSSiPbX0bUZM5M-jwtaS9_D_ze5cCJU_Dd_7frNXnIcCaDI2Vqj8xW1zfhDSCkVfM2qcFfU9cPDQ
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIiEuiDcpBRkJiQMKxI7jBxJCBbW0SMuJRXuzHD-gEmTbzVZi_z3jPLaN6IFLDrGjxOOZfN_48RngJS-8K2mQOecaL4LZHFlIyHUphFbKR-fS0MDsqzie8y-LarED43FHgwHba1O7dJ7UfPXrzZ_zzQcM-PddwCvxtkXMwnBH9MmRoGiM8BtwkyEypiVeM64utfcwGRo3zlz73AScOg3_f__UV6BquozyCi4d3YU7A6EkB70H3IOd0NyHW7NhyvwBLA6TSIR1G7KM5OT7yWfSb7naEKSrZJBVbUkajyVtOGtP23fEkkuBZ9JvbiG28eR3WNvcDjImD2F-dPjt03E-HKeQu0rwdW65jtKpiH9nyiKXPiJUW28ti8GHgJmTprGovCisw0TQhSIw56rCexoDi7Z8BLvNsglPgFRU1hFTS1khe6wLadMqCsFDVZdW6Fhn8Hq0oznrVTNMl20oYXqrG7S66axuVAYfk6m3NZPidXdjufphhgAyyDtESctIK4XZvA1Jth_pVLRKe8cYzeBV6iiTPAV7A-3aby_AD04KV-ZAykIgO2E6g_1JTYwnNy0eu9qM7mjSdCyiAjp0Bi-2xenJtEatCcuLVEclMTnJiwwe956xbVIplU7afxmoic9M2jwtaU5_dmrftFPIKfjef7z4KdxmyZ0RW5nah9316iI8Q9K0rp93kfAX5gQS9Q
  priority: 102
  providerName: Scholars Portal
Title Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/37898763
https://www.proquest.com/docview/2890111449
https://search.proquest.com/docview/2883581740
https://pubmed.ncbi.nlm.nih.gov/PMC10612304
https://doaj.org/article/0616313f158742ae8744064fa89dc221
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SFEovpe-6TRcVCj0UZ_2QJbm3bNg8ChtCaMrSi5D1aBe63iXeHPLvO5LtTUxuuehgSSDNQzMjzXwG-EITo_PU8pjSEhuWqRi9EBuXOWOlEMZp7a8GZufs9Ir-mBfzHWB9LUxI2tfV4qD-tzyoF39DbuV6qcd9ntj4YnaUBtCQhI53YRftbx-j9wh7GPL05TGCjRu0aHgYoG2K0X0pUf8HJigg9T88j-8ZpGGy5D3rc_wCnnduIzlsl_cSdmz9Cp7Ouofx1zCfeigIpW_JypGzX2cnpC2suiXolJIOPLUh_taVNHbdLJrvRJE7GGfSlrAQVRuytBsVqw6s5A1cHU9_Hp3G3U8TYl0wuokVLR3XwuEZnGaOcuPQICujVOassRbjozJ1SWFYojSGe9omNtO6SIxJnc2cyt_CXr2q7XsgRcorhwEkL9BHrBKufK4Eo7aocsVKV0XwraejXLfYGDLEFILJluoSqS4D1aWIYOJJvR3pca3Dh9X1H9lxVyJjWZ7mLi0ExuzKenB-dJqcEqXRWZZG8NUzSnrtQ24gXdsiAlywx7GSh5wnDH2QrIxgfzAStUYPu3tWy05rG-kfXfHsR7GN4PO228_0mWi1Xd34McJDxnGaRPCulYztlnIuSo_wF4EYyMxgz8MeFPGA6d2L9IfHT_0IzzIv5WhYM7EPe5vrG_sJPaZNNUI1mfMRPJlMzy8uR-HeAdsZFdheTn6PggL9B7sXGpQ
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVgIuiGcJFDASEgcUNXESx-GCWrRlF7orhFq0N8vxA3oguzTbQ_89M4l3txESlxxiJ7LHnplvxvZngLd5Yk2WujLO8wofgusYUYiLq0yISkrrjaHUwGwuJuf5l0WxCAm3Nmyr3NjEzlDbpaEc-SEtiKFe4i8_rv7EdGsUra6GKzRuwx4xpxcj2Dsez79937HtYfizOSojxWGL3g0NA_qpGKFMhbZg4I461v5_bfMN5zTcOHnDE508gPsBQrKjfswfwi3XPII7s7BI_hgWY6KF0OaaLT2b_ph-Zv0hq2uGAJUFItWWUQaWtW7VXrQfmGY7SmfWH2dhurHst1vrWAfikidwfjI--zSJwwUKsSlEvo51XvnSSI_2OOU-L61H56yt1tw76xzGSlXqk8KKRBsM_YxLHDemSKxNveNeZ09h1Cwb9wxYkZa1x2CyLBAv1kmpad-EyF1RZ1pUvo7g_UaOatXzZKguvpBC9VJXKHXVSV3JCI5J1NuaxHHdvVhe_lRBZRQiDZGlmU8LifG7dkTUjwDKa1lZw3kawTsaKEWaiKOBcu0PFGCDidNKHZVlIhCP8CqCg0FN1CAzLN4MtQoa3KrdfIvgzbaYvqRdaY1bXlEdSfRxZZ5EsN_PjG2XslJWxPYXgRzMmUGfhyXNxa-O3zvtOHGS_Pn_2_Ua7k7OZqfqdDr_-gLucZrV6FS5PIDR-vLKvUS0tK5fBZX4CyGMEfU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkSouiDeBAkZC4oDSTRzHD26ldOkCW_VA0d4sxw9Yic2umu2h_55xHksjblxyiG3JmffYM18A3rLM2SL3ImVM4YNTk2IU4lNVcK6kdMHaeDQwP-OnF-zLolz0VZVNX1ZZ22p5WP9eHdbLX21t5WZlJ0Od2OR8fpy3oCEZm2xcmNyGO2WBUjZk6gPOHiY-Q5OM5JMG_RqaBPRQKQYxCq3AyBG1eP3_WuUbbmlcMnnDB03vw70-eCRH3SYfwC1fP4T9eX89_ggWJxEQwthrsg5k9mP2mXTtVdcEQ1PSQ6g2JJ69ksZvmmXzgRjyF8yZdI0sxNSOrPzWpKaHLHkMF9OT78enaf_rhNSWnG1Tw1QQVga0xDkNTLiAbtk4Y2jwznvMklQestLxzFhM-qzPPLW2zJzLg6fBFE9gr17X_hmQMhdVwDRSlBgpVpkwsWKCM19WheEqVAm8H-ioNx1Chm4zC8l1R3WNVNct1bVM4GMk9W5mRLduX6wvf-qexxrZy4u8CHkpMXM3PkL0Y-gUjFTOUpon8C4ySkcdRG4gXbtWAtxwRLPSR0JkHCMRqhI4GM1E3bHj4YHVutfdRserV_QAKLwJvNkNx5WxHq3266s4R0bgOMGyBJ52krH7pEJIFXH-EpAjmRl983gEBb1F9h4E-_n_L30N--efpvrb7OzrC7hLo8Cjp6XyAPa2l1f-JYZQ2-pVqyt_AHZRGZ0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+IVIG+therapy+for+patients+with+sepsis%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Journal+of+translational+medicine&rft.au=Pan%2C+Bo&rft.au=Sun%2C+Pan&rft.au=Pei%2C+Renjun&rft.au=Lin%2C+Fangzhao&rft.date=2023-10-28&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft.spage=765&rft.epage=765&rft_id=info:doi/10.1186%2Fs12967-023-04592-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon